Morningstar agree. From this morning's HS:But Morningstar equity analyst Esther Holloway says the move on the complementary US business is “fair, with synergies expected”.
“On a preliminary assessment we view the offer as slightly value-destructive but not enough to move our fair value estimate, unchanged at $55 per share for wide-moat James Hardie,” Ms Holloway says. “We believe the market got this one wrong. We estimate the market is only ascribing about half the merger benefits and applies a lower 12 times enterprise value/EBITDA multiple on the combined group, implied by the preannouncement closing price.
“Using a 14 times EV/EBITDA multiple—the same as James Hardie’s multiple prior to the deal being announced and similar to Azek’s at its last undisturbed trading price — we think the bid price is fair assuming all $US300m of cost savings and revenue gains are achieved from fiscal 2030.”
She is also pencilling in cross-selling opportunities to generate $US500m in additional sales from fiscal 2030.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$41.13 |
Change
-0.780(1.86%) |
Mkt cap ! $17.68B | |||
| Open | High | Low | Value | Volume |
| $41.54 | $41.65 | $41.00 | $42.76M | 1.038M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $41.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $41.28 | 200 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| JHX (ASX) Chart |